# HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes

Study · id `cardio:ct-nct05623189` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05623189](<https://clinicaltrials.gov/study/NCT05623189>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05623189

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 218 participants.

## Technical summary

Registry record NCT05623189. Randomized; quadruple masking; primary purpose treatment. Start 2022-12-27 (actual); primary completion 2025-03-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 218 participants (enrolled count; ClinicalTrials.gov record NCT05623189, source copy `cardio:ctgov-nct05623189-2026-08-12`, retrieved 2026-10-26)
- Started: 2022-12-27 (actual) (ClinicalTrials.gov record NCT05623189, source copy `cardio:ctgov-nct05623189-2026-08-12`, retrieved 2026-10-26)
- Primary completion: 2025-03-31 (actual) (ClinicalTrials.gov record NCT05623189, source copy `cardio:ctgov-nct05623189-2026-08-12`, retrieved 2026-10-26)
- Completion: 2025-03-31 (actual) (ClinicalTrials.gov record NCT05623189, source copy `cardio:ctgov-nct05623189-2026-08-12`, retrieved 2026-10-26)
- Countries: United States; Hong Kong SAR China; Puerto Rico (ClinicalTrials.gov record NCT05623189, source copy `cardio:ctgov-nct05623189-2026-08-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05623189-2026-08-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes
- Acronym: CENTRICITY
- Condition: Nonalcoholic Steatohepatitis (NASH)
- Condition: Type 2 Diabetes
- Intervention (Drug): HTD1801
- Intervention (Drug): Placebo
- Lead sponsor: HighTide Therapeutics (Hong Kong) Limited
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 6873f3d72c5936e256b25646be12c04eede155a5f55dd8e391c760c57de752af
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
